quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:13:09·36d
INSIDERFiling
InflaRx N.V. logo

SEC Form 3 filed by InflaRx N.V.

IFRX· InflaRx N.V.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • IFRX
    InflaRx N.V.
    Health Care

Recent analyst ratings

  • Dec 3UpdateLeerink Partners$2.00
  • Sep 2UpdateH.C. Wainwright$6.00
  • May 29UpdateRaymond James$2.00
  • Apr 29UpdateCantor Fitzgerald$10.00
  • Apr 5UpdateGuggenheim$8.00
  • Feb 28UpdateGuggenheim-

Related

  • SEC14h
    SEC Form 6-K filed by InflaRx N.V.
  • SEC14d
    SEC Form 6-K filed by InflaRx N.V.
  • PR14d
    InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
  • SEC21d
    SEC Form 6-K filed by InflaRx N.V.
  • PR23d
    InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
  • SEC34d
    SEC Form 20-F filed by InflaRx N.V.
  • SEC35d
    SEC Form 6-K filed by InflaRx N.V.
  • PR35d
    InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022